NASDAQ · ASLN
ASLAN Pharmaceuticals Limited
$0.60-$0.10 (-14.27%)
ASLAN Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
Loading market information…
NASDAQ · ONCT · USD
Stock price, earnings
Quote as of Dec 2, 2024, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Oncternal Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.04% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Oncternal Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating cancer treatments for diseases where current medical options are insufficient. Its clinical-stage portfolio features zilovertamab, a humanized monoclonal antibody designed to bind to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule that works by inhibiting the biological activity of ETS-family transcription factor oncoproteins. Additionally, Oncternal is advancing ONCT-808, a chimeric antigen receptor T-cell (CAR-T) therapy candidate also targeting ROR1, as well as ONCT-534, a dual-action androgen receptor inhibitor aimed at treating castration-resistant prostate cancer and other cancers driven by androgen receptors. The company holds various license agreements with institutions such as the Regents of the University of California, Georgetown University, The University of Texas MD Anderson Cancer Center, Shanghai Pharmaceutical (USA) Inc., and the University of Tennessee Research Foundation. Furthermore, it engages in a research collaboration with Celularity Inc. to explore placental-derived cellular therapies that also target ROR1. Its headquarters are located in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:48 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $106.00K-47.0% vs estimate |
| Q1 2023 | May 4, 2023 | -$4.00+4.76% vs estimate | $203.00K+19.41% vs estimate |
|---|
| Q4 2022 | Mar 9, 2023 | -$4.00+9.09% vs estimate | $171.00K-48.18% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.60-$0.10 (-14.27%)
ASLAN Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
$0.07-$0.07 (-50.87%)
VBI Vaccines Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.16% below the high.
$0.24-$0.00 (-0.82%)
PolarityTE, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.32% below the high.
$0.42+$0.42 (+100.0%)
CareMax, Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.94% below the high.
$0.47-$0.12 (-20.74%)
Avinger, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.15% below the high.
$0.03$0.00 (0.0%)
Cassava Sciences, Inc. Warrant’s quoted price sits in the lower half of its reported 52-week range, 99.73% below the high.
$0.38-$0.01 (-1.56%)
NeuBase Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.49% below the high.
$0.41$0.00 (0.0%)
CohBar, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.41% below the high.
